PAIGE.AI
LIVE

Serial Number

87843838

Owner

PAIGE.AI, Inc.

Attorney

Mark Leonardo

First Use Date

Feb 20, 2019

Filing Date

Mar 21, 2018

Add to watchlist:

No watchlists yet
View on USPTO

PAIGE.AI Trademark

Serial Number: 87843838 • Registration: 6420234

PAIGE.AI is a trademark filed by PAIGE.AI, Inc. on March 21, 2018. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

PAIGE.AI, Inc. (12 trademarks)

New York, NY 10036

Entity Type: 03

Trademark Details

Filing Date

March 21, 2018

Registration Date

July 13, 2021

First Use Anywhere

February 20, 2019

First Use in Commerce

February 20, 2019

Published for Opposition

October 23, 2018

Goods & Services

Medical services; cancer therapy services; medical testing, namely, the review and analysis of patients' clinical slides to identify additional recommended medical testing; medical testing for the diagnosis of diseases, states, or conditions; medical testing for evaluation of prognosis relating to diseases, states, or conditions; medical testing for the monitoring of diseases, states, or conditions; medical testing to detect or identify predispositions to diseases, states, or conditions; medical testing to detect or determine the recurrence of diseases, states, or conditions; medical testing to detect, monitor, or evaluate responses to treatment of diseases, states, or conditions; medical testing to evaluate clinical management of diseases, states, or conditions; medical testing for selection of treatment for diseases, states, or conditions; medical testing to evaluate or facilitate prevention of diseases, states, or conditions; medical testing to select, facilitate, monitor, or evaluate palliation or treatment of diseases, states or conditions; medical testing in the field of cancer; medical testing in the field of oncology; medical diagnostic testing, monitoring, or reporting services; medical analysis or advisory services in the field of cancer; medical analysis or advisory services in the field of oncology; medical analysis or advisory services for medical treatment; medical analysis or advisory services for the diagnosis of diseases, states, or conditions; medical analysis or advisory services for the evaluation of prognosis relating to diseases, states, or conditions; medical analysis or advisory services relating to monitoring diseases, states, or conditions; medical analysis or advisory services relating to the detection or identification of predispositions to diseases, states, or conditions; medical analysis or advisory services relating to the detection or determination of the recurrence of diseases, states, or conditions; medical analysis or advisory services relating to the detection, monitoring, or evaluation of responses to treatment of diseases, states, or conditions; medical analysis or advisory services relating to the clinical management of diseases, states, or conditions; medical analysis or advisory services relating to the selection of treatment for diseases, states, or conditions; medical analysis or advisory services relating to the prevention of diseases, states, or conditions; medical analysis or advisory services relating to the palliation or treatment of diseases, states or conditions; qualitative image analysis in the field of digital pathology for medical purposes; quantitative image analysis in the field of digital pathology for medical purposes; providing non-research related medical information via the internet; medical analysis services for the diagnosis of cancer by reviewing pathological samples on slides

Software as a service (SaaS) services featuring software for artificial intelligence, machine learning, deep learning, statistical learning, data mining, and contextual prediction; software as a service (SaaS) services featuring software for use in disease pathology, namely, software that reads digital slides and provides diagnoses; software as a service (SaaS) services featuring software for use in diagnosis of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in evaluation of prognosis relating to diseases, states, or conditions; software as a service (SaaS) services featuring software for use in monitoring of diseases, states, or conditions; software as a service (SaaS) services featuring software for use to detect or identify predispositions to diseases, states, or conditions; software as a service (SaaS) services featuring software to detect the recurrence of diseases, states, or conditions; software as a service (SaaS) services featuring software to detect, monitor, or evaluate patients' responses to treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in clinical management of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in the selection of treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in prevention of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in palliation or treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in research or development in the field of life sciences; software as a service (SaaS) services featuring software for use in research or development in the field of medicine; software as a service (SaaS) services featuring software for use in research or development in the field of healthcare; software as a service (SaaS) services featuring software for use in research or development in the field of cancer; software as a service (SaaS) services featuring software for use in research or development in the field of oncology; software as a service (SaaS) services featuring software for use in research or development in the field of pathology; design and development of AI-powered computer software that analyzes clinical pathology slides and diagnoses diseases; medical research; scientific research and development services in the field of pathology; research and development services in the field of medicine; research and development services in the field of cancer; research and development services in the field of healthcare; research and development services in the field of life sciences; research and development services in the field of oncology; medical and scientific research services in the field of pathology; medical and scientific research services in the field of cancer; medical and scientific research services in the field of healthcare; medical and scientific research services in the field of life sciences; medical and scientific research services in the field of oncology; research and development of technology in the field of pathology; research and development of technology in the field of medicine; research and development of technology in the field of cancer; research and development of technology in the field of healthcare; research and development of technology in the field of life sciences; research and development of technology in the field of oncology; providing medical research and scientific research information via the internet; electronic scanning of clinical pathology slides; software as a service services (SaaS) featuring software for use in the analysis of clinical pathology slides; medical and scientific testing services for research purposes

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 13, 2026 REM1
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 17, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 17, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 17, 2026 REAP
REGISTERED-PRINCIPAL REGISTER
Jul 13, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jun 8, 2021 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jun 7, 2021 CNPR
STATEMENT OF USE PROCESSING COMPLETE
May 21, 2021 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 21, 2021 AITU
USE AMENDMENT FILED
May 12, 2021 IUAF
TEAS STATEMENT OF USE RECEIVED
May 12, 2021 EISU
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 1, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 1, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 1, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 1, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 1, 2021 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 1, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 1, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 1, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 1, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 1, 2021 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 15, 2020 EXRA
SOU EXTENSION 4 GRANTED
Dec 11, 2020 EX4G
SOU EXTENSION 4 FILED
Dec 11, 2020 EXT4
SOU TEAS EXTENSION RECEIVED
Dec 11, 2020 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 12, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 12, 2020 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 12, 2020 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 8, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 8, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 8, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 8, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 8, 2020 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 20, 2020 EXRA
SOU EXTENSION 3 GRANTED
Jun 18, 2020 EX3G
SOU EXTENSION 3 FILED
Jun 18, 2020 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 18, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 20, 2019 EXRA
SOU EXTENSION 2 GRANTED
Dec 18, 2019 EX2G
SOU EXTENSION 2 FILED
Dec 18, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 18, 2019 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 14, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 14, 2019 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 18, 2019 EXRA
SOU EXTENSION 1 GRANTED
Jun 14, 2019 EX1G
SOU EXTENSION 1 FILED
Jun 14, 2019 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 14, 2019 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 18, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 23, 2018 NPUB
PUBLISHED FOR OPPOSITION
Oct 23, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 3, 2018 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 20, 2018 PREV
ASSIGNED TO LIE
Sep 17, 2018 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 5, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 6, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 6, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 6, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 11, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jul 11, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jul 11, 2018 CNRT
ASSIGNED TO EXAMINER
Jul 2, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 28, 2018 NWOS
NEW APPLICATION ENTERED
Mar 24, 2018 NWAP